⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
ASTRAZEN - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.6
| Stock Code | ASTRAZEN | Market Cap | 21,929 Cr. | Current Price | 8,745 ₹ | High / Low | 10,691 ₹ |
| Stock P/E | 94.9 | Book Value | 320 ₹ | Dividend Yield | 0.37 % | ROCE | 33.4 % |
| ROE | 23.6 % | Face Value | 2.00 ₹ | DMA 50 | 8,692 ₹ | DMA 200 | 8,637 ₹ |
| Chg in FII Hold | -0.03 % | Chg in DII Hold | 0.29 % | PAT Qtr | 58.1 Cr. | PAT Prev Qtr | 56.1 Cr. |
| RSI | 58.3 | MACD | -46.6 | Volume | 6,452 | Avg Vol 1Wk | 4,919 |
| Low price | 6,502 ₹ | High price | 10,691 ₹ | PEG Ratio | 2.19 | Debt to equity | 0.04 |
| 52w Index | 53.5 % | Qtr Profit Var | 51.3 % | EPS | 79.7 ₹ | Industry PE | 28.2 |
📊 Core Financials
- Revenue & Profitability: Quarterly PAT improved to 58.1 Cr. from 56.1 Cr. EPS stands at 79.7 ₹, showing consistent earnings strength.
- Margins: ROCE at 33.4% and ROE at 23.6% highlight strong profitability and efficient use of capital.
- Debt: Debt-to-equity ratio of 0.04 indicates negligible leverage, enhancing financial resilience.
- Cash Flow: Stable profitability supports healthy cash generation.
💹 Valuation Indicators
- P/E Ratio: 94.9, far above industry average of 28.2, suggesting significant overvaluation.
- P/B Ratio: Current price (8745 ₹) vs. book value (320 ₹) reflects a steep premium.
- PEG Ratio: 2.19, indicating growth does not fully justify valuation multiples.
- Intrinsic Value: Current market price appears stretched relative to fundamentals.
🏢 Business Model & Competitive Advantage
- Pharmaceutical focus with strong brand recognition and innovative pipeline.
- Efficient capital allocation with high ROCE and ROE.
- Low debt structure provides long-term sustainability.
📈 Entry Zone & Long-Term Guidance
- Entry Zone: Attractive accumulation range lies between 6,800–7,200 ₹, given current overvaluation.
- Long-Term Holding: Strong fundamentals make it suitable for long-term investors, but entry should be timed closer to fair value.
✅ Positive
- High ROCE (33.4%) and ROE (23.6%) show strong efficiency.
- Debt-free balance sheet ensures financial stability.
- Quarterly profit growth with EPS strength